Alzheimer’s Drug Discovery Foundation & The Association for Frontotemporal Degeneration 2026

Request for proposals: accelerating drug discovery for frontotemporal degeneration

There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The ADDF and the AFTD seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy, etc.) drug development programs for FTD through this request for proposals (RFP).

LOI deadline: May 11, 2026

Full proposal deadline: July 20, 2026

The award is around USD 300.000

Eligibility

Funding is open to researchers and clinicians in the U.S. and worldwide working in:

• Academic medical centers and universities or nonprofits; industry partnerships are encouraged
• Biotechnology companies that demonstrate a clear need for nonprofit funding; existing companies and new spinouts are both eligible